Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5

Hideo Nakamura, Hideki Kasuya, John T. Mullen, Sam S. Yoon, Timothy M. Pawlik, Soundararajalu Chandrasekhar, James M. Donahue, E. Antonio Chiocca, Richard Y. Chung, Kenneth K. Tanabe

Research output: Contribution to journalArticle

Abstract

Myb34.5 is a herpes simplex virus 1 (HSV-1) mutant deleted in the gene for ribonucleotide reductase (ICP6). It also carries a version of γ134.5 (a viral gene product that promotes the dephosphorylation of eIF-2α) that is under control of the E2F-responsive cellular B-myb promoter, rather than of its endogenous promoter. Myb34.5 replication in tumor cells results in their destruction (oncolysis). γ134.5 expression by HSV-1 subverts an important cell defense mechanism against viral replication by preventing shutoff of protein synthesis after viral infection. Infection of colon carcinoma cells with Myb34.5 results in greater eIF-2α dephosphorylation and viral replication compared with infection with HSV-1 mutants completely defective in γ134.5 expression. In contrast, infection of normal hepatocytes with Myb34.5 results in low levels of eIF-2α dephosphorylation and viral replication that are similar to those observed with HSV-1 mutants completely defective in γ134.5 and ICP6. When administered intravascularly into mice with diffuse liver metastases, Myb34.5 has greater antineoplastic activity than HSV-1 mutants with completely defective γ134.5 expression and more restricted biodistribution compared with HSV-1 mutants with wild-type γ134.5 expression. Myb34.5 displays reduced virulence and toxicity compared to HSV-1 mutants with wild-type γ134.5 expression. Portal venous administration of Myb34.5 significantly reduces liver tumor burden in and prolongs the life of mice with diffuse liver metastases. Preexisting Ab's to HSV-1 do not reduce the antitumor efficacy of Myb34.5 in vivo.

Original languageEnglish (US)
Pages (from-to)871-882
Number of pages12
JournalJournal of Clinical Investigation
Volume109
Issue number7
DOIs
StatePublished - 2002
Externally publishedYes

Fingerprint

Human Herpesvirus 1
Simplexvirus
Neoplasm Metastasis
Liver
Infection
Ribonucleotide Reductases
Viral Proteins
Virus Diseases
Tumor Burden
Antineoplastic Agents
Virulence
Hepatocytes
Colon
Carcinoma
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nakamura, H., Kasuya, H., Mullen, J. T., Yoon, S. S., Pawlik, T. M., Chandrasekhar, S., ... Tanabe, K. K. (2002). Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. Journal of Clinical Investigation, 109(7), 871-882. https://doi.org/10.1172/JCI200210623

Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. / Nakamura, Hideo; Kasuya, Hideki; Mullen, John T.; Yoon, Sam S.; Pawlik, Timothy M.; Chandrasekhar, Soundararajalu; Donahue, James M.; Antonio Chiocca, E.; Chung, Richard Y.; Tanabe, Kenneth K.

In: Journal of Clinical Investigation, Vol. 109, No. 7, 2002, p. 871-882.

Research output: Contribution to journalArticle

Nakamura, H, Kasuya, H, Mullen, JT, Yoon, SS, Pawlik, TM, Chandrasekhar, S, Donahue, JM, Antonio Chiocca, E, Chung, RY & Tanabe, KK 2002, 'Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5', Journal of Clinical Investigation, vol. 109, no. 7, pp. 871-882. https://doi.org/10.1172/JCI200210623
Nakamura, Hideo ; Kasuya, Hideki ; Mullen, John T. ; Yoon, Sam S. ; Pawlik, Timothy M. ; Chandrasekhar, Soundararajalu ; Donahue, James M. ; Antonio Chiocca, E. ; Chung, Richard Y. ; Tanabe, Kenneth K. / Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5. In: Journal of Clinical Investigation. 2002 ; Vol. 109, No. 7. pp. 871-882.
@article{b25954e19b3343ba96a7d83f2f057e80,
title = "Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5",
abstract = "Myb34.5 is a herpes simplex virus 1 (HSV-1) mutant deleted in the gene for ribonucleotide reductase (ICP6). It also carries a version of γ134.5 (a viral gene product that promotes the dephosphorylation of eIF-2α) that is under control of the E2F-responsive cellular B-myb promoter, rather than of its endogenous promoter. Myb34.5 replication in tumor cells results in their destruction (oncolysis). γ134.5 expression by HSV-1 subverts an important cell defense mechanism against viral replication by preventing shutoff of protein synthesis after viral infection. Infection of colon carcinoma cells with Myb34.5 results in greater eIF-2α dephosphorylation and viral replication compared with infection with HSV-1 mutants completely defective in γ134.5 expression. In contrast, infection of normal hepatocytes with Myb34.5 results in low levels of eIF-2α dephosphorylation and viral replication that are similar to those observed with HSV-1 mutants completely defective in γ134.5 and ICP6. When administered intravascularly into mice with diffuse liver metastases, Myb34.5 has greater antineoplastic activity than HSV-1 mutants with completely defective γ134.5 expression and more restricted biodistribution compared with HSV-1 mutants with wild-type γ134.5 expression. Myb34.5 displays reduced virulence and toxicity compared to HSV-1 mutants with wild-type γ134.5 expression. Portal venous administration of Myb34.5 significantly reduces liver tumor burden in and prolongs the life of mice with diffuse liver metastases. Preexisting Ab's to HSV-1 do not reduce the antitumor efficacy of Myb34.5 in vivo.",
author = "Hideo Nakamura and Hideki Kasuya and Mullen, {John T.} and Yoon, {Sam S.} and Pawlik, {Timothy M.} and Soundararajalu Chandrasekhar and Donahue, {James M.} and {Antonio Chiocca}, E. and Chung, {Richard Y.} and Tanabe, {Kenneth K.}",
year = "2002",
doi = "10.1172/JCI200210623",
language = "English (US)",
volume = "109",
pages = "871--882",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "7",

}

TY - JOUR

T1 - Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5

AU - Nakamura, Hideo

AU - Kasuya, Hideki

AU - Mullen, John T.

AU - Yoon, Sam S.

AU - Pawlik, Timothy M.

AU - Chandrasekhar, Soundararajalu

AU - Donahue, James M.

AU - Antonio Chiocca, E.

AU - Chung, Richard Y.

AU - Tanabe, Kenneth K.

PY - 2002

Y1 - 2002

N2 - Myb34.5 is a herpes simplex virus 1 (HSV-1) mutant deleted in the gene for ribonucleotide reductase (ICP6). It also carries a version of γ134.5 (a viral gene product that promotes the dephosphorylation of eIF-2α) that is under control of the E2F-responsive cellular B-myb promoter, rather than of its endogenous promoter. Myb34.5 replication in tumor cells results in their destruction (oncolysis). γ134.5 expression by HSV-1 subverts an important cell defense mechanism against viral replication by preventing shutoff of protein synthesis after viral infection. Infection of colon carcinoma cells with Myb34.5 results in greater eIF-2α dephosphorylation and viral replication compared with infection with HSV-1 mutants completely defective in γ134.5 expression. In contrast, infection of normal hepatocytes with Myb34.5 results in low levels of eIF-2α dephosphorylation and viral replication that are similar to those observed with HSV-1 mutants completely defective in γ134.5 and ICP6. When administered intravascularly into mice with diffuse liver metastases, Myb34.5 has greater antineoplastic activity than HSV-1 mutants with completely defective γ134.5 expression and more restricted biodistribution compared with HSV-1 mutants with wild-type γ134.5 expression. Myb34.5 displays reduced virulence and toxicity compared to HSV-1 mutants with wild-type γ134.5 expression. Portal venous administration of Myb34.5 significantly reduces liver tumor burden in and prolongs the life of mice with diffuse liver metastases. Preexisting Ab's to HSV-1 do not reduce the antitumor efficacy of Myb34.5 in vivo.

AB - Myb34.5 is a herpes simplex virus 1 (HSV-1) mutant deleted in the gene for ribonucleotide reductase (ICP6). It also carries a version of γ134.5 (a viral gene product that promotes the dephosphorylation of eIF-2α) that is under control of the E2F-responsive cellular B-myb promoter, rather than of its endogenous promoter. Myb34.5 replication in tumor cells results in their destruction (oncolysis). γ134.5 expression by HSV-1 subverts an important cell defense mechanism against viral replication by preventing shutoff of protein synthesis after viral infection. Infection of colon carcinoma cells with Myb34.5 results in greater eIF-2α dephosphorylation and viral replication compared with infection with HSV-1 mutants completely defective in γ134.5 expression. In contrast, infection of normal hepatocytes with Myb34.5 results in low levels of eIF-2α dephosphorylation and viral replication that are similar to those observed with HSV-1 mutants completely defective in γ134.5 and ICP6. When administered intravascularly into mice with diffuse liver metastases, Myb34.5 has greater antineoplastic activity than HSV-1 mutants with completely defective γ134.5 expression and more restricted biodistribution compared with HSV-1 mutants with wild-type γ134.5 expression. Myb34.5 displays reduced virulence and toxicity compared to HSV-1 mutants with wild-type γ134.5 expression. Portal venous administration of Myb34.5 significantly reduces liver tumor burden in and prolongs the life of mice with diffuse liver metastases. Preexisting Ab's to HSV-1 do not reduce the antitumor efficacy of Myb34.5 in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0036212495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036212495&partnerID=8YFLogxK

U2 - 10.1172/JCI200210623

DO - 10.1172/JCI200210623

M3 - Article

C2 - 11927614

AN - SCOPUS:0036212495

VL - 109

SP - 871

EP - 882

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 7

ER -